The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, awarded a single-award Indefinite Delivery Contract valued up to $146,300,000 to Southern Research Institute, a non-profit research organization, to develop and employ animal and animal replacement models of infectious diseases. The contract will support screening, product evaluation, and eventual clinical evaluation of vaccines, therapeutics, and...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a single-award, $146.3 million Indefinite Delivery Contract (IDC) to The Research Foundation For The State University Of New York to develop and employ animal and animal replacement models of infectious diseases for screening, product evaluation, and eventual clinical evaluation. This IDC contains four task areas: Task Area A - Small Animal Models of Infectious Diseases Task Area B - Non-Human Primate Models of...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, awarded a $146.3 million Indefinite Delivery Contract (IDC) to Institute For Clinical Pharmacodynamics, Inc., a for-profit organization, to provide pre-clinical models of infectious diseases under Task Area C. The period of performance is from July 15, 2024 to July 14, 2031. The contract is a follow-on to a previous Preclinical Models of Infectious Diseases...
This indefinite delivery contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the University of Chicago, a private non-profit educational institution. The $146.3M contract is for a 7-year ordering period and supports the pre-clinical evaluation and development of animal and animal replacement models of infectious diseases to screen and evaluate candidate countermeasures such as therapeutics, vaccines, and diagnostics. The contract is...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, has awarded a $146.3 million single-award Indefinite Delivery Contract to the University of Saskatchewan. The contract covers a 7-year period from July 2024 to July 2031 and includes three main task areas: A. Development and evaluation of small animal models for infectious diseases B. Development and evaluation of non-human primate models for infectious diseases C. Development and evaluation of animal...
This single-award Indefinite Delivery Contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Battelle Memorial Institute, a non-profit organization and manufacturer of goods, to provide pre-clinical models of infectious diseases. The $146.3 million, 7-year contract has a completion date of July 14, 2031 and was awarded on July 15, 2024. The contract aims to develop and employ animal and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a single-award Indefinite Delivery Contract (IDC) worth up to $146,300,000 to The Johns Hopkins University to provide pre-clinical models of infectious diseases. The contract has a period of performance from July 2024 to July 2031. The contract encompasses four task areas: (A) Small Animal Models, (B) Non-Human Primate Models, (C) Animal Replacement and Non-Traditional Animal Models, and (D) Generation and Distribution...
This indefinite delivery contract, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. federal government, aims to provide the capability and capacity to develop and employ animal and animal replacement models of infectious diseases for screening, product evaluation, and eventual clinical evaluation. The single-award contract, with a 7-year ordering period and a ceiling value of $146.3 million, was awarded to Sigmovir Biosystems, Inc., a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded this $146.3 million single award Indefinite Delivery Contract to the University of Louisville to provide preclinical models of infectious diseases over a 7-year ordering period ending in 2031. The contract supports NIAID's mission to facilitate research on understanding, treating, and preventing infectious diseases by enabling the development and refinement of small animal, non-human primate, and non-traditional animal...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a single-award, $146.3M Indefinite Delivery Contract to Trustees of Tufts College, doing business as Tufts University School of Medicine, to provide pre-clinical research and development services related to infectious disease models. The contract has a 7-year ordering period and aims to support NIAID's Division of Microbiology and Infectious Diseases in developing and refining animal and animal replacement models for...
This indefinite delivery contract with the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, aims to provide preclinical models of infectious diseases to support the development and evaluation of medical countermeasures. The single award contract, valued at up to $146.3 million, has a 7-year ordering period and covers three task areas:
Task Area A - Small Animal Models of Infectious Diseases
Task Area B - Non-Human Primate Models of Infectious Diseases
Task Area C - Animal Replacement and Non-traditional Animal Models of Infectious Diseases
The prime contractor, Colorado State University's Sponsored Programs division, will be responsible for all contracted work, which may include subcontracting to leverage additional expertise and resources. The services will support NIAID's research to understand, treat, and prevent a range of infectious diseases, including those with pandemic potential, antimicrobial resistant infections, and diseases caused by pathogens on NIAID's Emerging Infectious Diseases/Pathogens list. This contract is intended to bridge the gap between in vitro testing and eventual clinical evaluation of medical countermeasures.